E-mail:pr@chugai-pharm.co.jp URL:http://www.chugai-pharm.co.jp



## Translation

Extension of the Shelf-Life for the Anti-Influenza Virus Drug Tamiflu<sup>®</sup> Capsules 75

July 01, 2013 (TOKYO) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama] (hereafter, "Chugai") today announced the extension of the shelf-life for the anti-influenza virus drug Tamiflu<sup>®</sup> Capsules 75 imported from F. Hoffmann-La Roche Ltd. [Head office: Basel, Switzerland; CEO: Severin Schwan] (hereafter, "Roche") and marketed in Japan by Chugai from the current 7 years to 10 years with the products manufactured in the future.

Chugai decided to extend the shelf-life for Tamiflu<sup>®</sup> Capsules 75 up to 10 years based on the stability study conducted by Roche.

Future stock of Tamiflu<sup>®</sup> Dry Syrup 3% (Japan Formulation) will have a shelf-life of 7 years.

Chugai will ensure a stable supply of Tamiflu<sup>®</sup> in times of future influenza epidemic.

Tamiflu<sup>®</sup> is trademark of F. Hoffmann-La Roche Ltd., Basel, Switzerland.